Table 2.

Systemic, conversion, and neo/-adjuvant therapy^*.

		All systemic		R0–1 resection		R2-resected/LAT		”Systemic therapy alone”
		1060	100	324	100	72	100	664	100
Resectability	Resectable upfront	305	29%	228	70%	34	47%	43	7%
	Borderline/unresectable converted	137	13%	96	30%	38	53%	3	1%
	Borderline still unsresectable	51	5%	0	0%	0	0%	51	8%
	Unresectable	567	53%	0	0%	0	0%	567	85%
1st line drug combination	Comb. CT & anti-EGFR	139	13%	59	18%	10	14%	70	11%
	Comb. CT & anti-VEGF	550	52%	147	45%	39	54%	364	55%
	Comb. CT (no biological)	224	21%	90	28%	19	26%	115	17%
	Single CT +/- anti-VEGF/-EGFR	147	14%	28	9%	4	6%	115	17%
Lines of therapy	1 line of therapy	414	39%	155	48%	21	29%	238	36%
	2 lines of therapy	271	26%	78	24%	25	35%	168	25%
	3+ lines of therapy	375	35%	91	28%	26	36%	258	39%
Exposure to drugs during trajectory	Fluoropyrimidine	1051	99%	320	99%	72	100%	659	99%
	Oxaliplatin	840	79%	258	80%	62	86%	520	78%
	Irinotecan	765	72%	218	67%	52	72%	495	75%
	Bevacizumab	758	72%	206	64%	53	74%	499	75%
	Anti-EGFR	341	32%	115	35%	19	26%	207	31%
	Aflibercept	75	7%	19	6%	5	7%	51	8%
	Regorafenib	162	15%	29	9%	16	22%	117	18%
	Trifluridin/tipiracil	74	7%	20	6%	6	8%	48	7%
Time on systemic therapy during trajectory	Median (IQR) time on therapy (months)	11·1	(6; 19)	8·5	(6; 17)	14·1	(8; 24)	12·4	(6; 20)

IQR = interquartile range.

^⁎Excluded are 23 patients with best supportive care only and 3 patients with metastasectomy without systemic therapy.